FOUNDER, CHAIRMAN & CEO
Minna is the leading inventor of DiagMMR® with more than 25 years of experience in the field of Lynch syndrome research and has had an active role in both the identification of the LS related genes and mutations as well as the bettering of LS recognition with more than 60 scientific publications in the field. Minna is also an active member of the International Society for Gastrointestinal Hereditary Tumours, InSiGHT.
CHIEF FINANCIAL OFFICER
Niklas is responsible for operational and financial management, investor relations, and shareholder management. He has gained experience in investment banking and other industries before joining LS CancerDiag.
CHIEF BUSINESS OFFICER
Philippe brings a wealth of experience from corporate roles in major blue-chip companies on an international level in Europe and the Americas, with responsibilities for strategy development, change management, procurement and logistics. He is responsible for commercial partnerships, international expansion, marketing & communications, strategic planning.
CHIEF SCIENTIFIC OFFICER
Minttu has worked on Lynch syndrome research in Prof. Nyström ́s lab for over 10 years and is a co-inventor of DiagMMR®. Her doctoral thesis, “Recognizing Lynch syndrome by DNA mismatch repair deficiency” focused on pathogenicity assessment and interpretation of LS associated mutations and functional detection of reduced mismatch repair. She is responsible for scientific research, product development, and laboratory management.
Jaana has vast experience in cell culture and works to ensure the meticulous handling of patient samples from sampling to testing. In addition to coordinating the sample handling and running the cell culture processes, she assists with other processes of the DiagMMR® testing and is responsible for quality management.
Mariann is responsible for the laboratory production of the DiagMMR® assay and result interpretation. She specializes in the quantitative detection method and has broad experience in MMR research, cell culture and biotechnology. In her doctoral dissertation "Reduced mismatch repair gene expression and functional deficiency as indicators of Lynch syndrome" she studied the functional effect of lowered MMR gene expression as an indication of Lynch syndrome and assessed the pathogenicity of MMR gene variants of uncertain clinical significance.
Anu has extensive and versatile laboratory work experience, particularly in cell culture and molecular techniques. She supports the daily laboratory operations at LS CancerDiag and participates in DiagMMR® sample handling.